松龄血脉康胶囊治疗原发性高血压的药品临床综合评价  

Comprehensive Clinical Evaluation on Songling Xuemaikang Capsules in the Treatment of Essential Hypertension

作　　者：王海征[1] 冯英楠 庄伟[1] 李晓曦 张兰[1] 董宪喆 WANG Haizheng;FENG Yingnan;ZHUANG Wei;LI Xiaoxi;ZHANG Lan;DONG Xianzhe(Dept.of Pharmacy,Xuanwu Hospital of Capital Medical University,Beijing 100053,China)

机构地区：[1]首都医科大学宣武医院药学部,北京100053

出　　处：《中国医院用药评价与分析》2024年第10期1253-1256,1261,共5页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：首都卫生发展科研专项(首发2024-2-2019);北京市医院管理中心“登峰”人才培养计划项目(No.DFL20190803);中国科学技术协会科技智库青年人才计划(20220615ZZ07110070)。

摘　　要：目的:评价松龄血脉康胶囊治疗原发性高血压的临床综合价值,以更好地指导临床用药。方法:检索万方数据库、中国知网、PubMed等中英文数据库(检索时间为建库至2023年12月);通过药品生产企业和相关市场数据,获取松龄血脉康胶囊的药品说明书以及药品价格等数据。按照《药品临床综合评价管理指南(2021年版试行)》中的方法,对松龄血脉康胶囊治疗原发性高血压的安全性、有效性、经济性、创新性、适宜性和可及性6个价值维度进行分析。结果:初筛获得272篇文献,最终纳入9篇随机对照试验文献。在有效性和安全性方面,松龄血脉康胶囊可降低患者的收缩压及舒张压,降压效果与单纯使用西药(氯沙坦钾片)相当,其不良反应发生率较少,且较轻微。在经济性方面,按药品说明书推荐剂量服用,松龄血脉康胶囊的每日负担水平较低。松龄血脉康胶囊在治疗高血压理念上具有创新性,是国家重点新产品。松龄血脉康胶囊的适宜性和可及性良好。结论:松龄血脉康胶囊对于原发性高血压(Ⅰ—Ⅱ级)患者具有良好的临床应用价值。OBJECTIVE:To evaluate the clinical comprehensive value of Songling Xuemaikang capsules in the treatment of essential hypertension,so as to better guide clinical medication.METHODS:Chinese and English databases such as Wanfang Data,CNKI and PubMed were searched(the retrieval time was from the establishment of the database to Dec.2023).Data including the dispensatory and price of Songling Xuemaikang capsules were obtained through drug manufacturers and relevant market data.Six value dimensions of safety,efficacy,economical efficiency,innovation,appropriateness and accessibility of Songling Xuemaikang capsules in the treatment of essential hypertension were analyzed in accordance with the methodology in the Guidelines for the Management of Clinical Comprehensive Evaluation of Drugs(Trial Version 2021).RESULTS:A total of 272 studies were obtained from the initial screening,and 9 randomized controlled trials were finally enrolled.In terms of the efficacy and safety,Songling Xuemaikang capsules could reduce patients’systolic and diastolic blood pressure,which had equivalent blood pressure-lowering effect as Western medicine alone(Losartan potassium tablets),with lower incidence of adverse drug reactions.In terms of economical efficiency,the daily cost of Songling Xuemaikang capsules was lower when taken recommended dosage according to the dispensatory.Songling Xuemaikang capsules was innovative in the concept of treating hypertension and was the national key new product.Songling Xuemaikang capsules had better appropriateness and accessibility.CONCLUSIONS:Songling Xuemaikang capsules has good clinical application value for patients with essential hypertension(gradeⅠtoⅡ).

关 键 词：松龄血脉康胶囊 原发性高血压 药品临床综合评价 

分 类 号：R932[医药卫生—生药学]